(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 3 February 2005 (03.02.2005)

PCT

(10) International Publication Number WO 2005/010213 A2

(51) International Patent Classification7:

C12Q 1/68

(21) International Application Number:

PCT/US2004/022959

(22) International Filing Date: 16 July 2004 (16.07.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/487,906

17 July 2003 (17.07.2003)


- (71) Applicants (for all designated States except US): PA-CIFIC EDGE BIOTECHNOLOGY, LTD. [NZ/NZ]: Centre for Innovation, 87 St. David Street, Dunedin (NZ). FARMER, Charles, Davis, Jr. [US/US]; 97 Giles Road, East Kingston, NH 03827 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): GUILFORD, Parry, John [NZ/NZ]; 38 Riccarton Road East, East

Taieri, Dunedin (NZ). HOLYOAKE, Andrew, John [NZ/NZ]; 41 Rychill Street, Dunedin (NZ).

- (74) Agents: BORSON, D., Benjamin et al.; FLIESLER MEYER LLP, Four Embarcadero Center, Fourth Floor, San Francisco, California 94111-4156 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,

[Continued on next page]

(54) Title: MARKERS FOR DETECTION OF GASTRIC CANCER



(57) Abstract: Early detection of tumors is a major determinant of survival of patients suffering from tumors, including gastric tumors. Members of the GTM gene family can be over-expressed in gastric tumor tissue and other tumor tissue, and thus can be used as markers for gastric and other types of cancer. GTM proteins can be released from cancer cells, and can reach sufficiently high concentrations in the serum and/or other fluids to permit their detection. Thus, methods and test kits for detection and quantification of GTM can provide a valuable tool for diagnosis of gastric cancer.



WO 2005/010213 A2



SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.